Mobile website
Prompt Report
Inhibiting effect of CD20 promoter-driven recombinant adenovirous-stTRAIL on lymphoma cell growth
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective: To evaluate the effect of a CD20 promoter-driven recombinant adenovirus-soluble trimeric tumor necrosis factor-related apoptosis-inducing ligand (stTRAIL) vector on the growth of lymphoma cells in vitro . Methods: An adenoviral vector encoding stTRAIL driven by the CD20 promoter whose activity was confirmed in lymphoma cell lines by luciferase assay was constructed. The constructed vector was infected into CD20 positive and CD20 negative lymphoma cell lines respectively. Protein content of stTRAIL was assessed by Western blotting and cell viability was determined by MTT assay in infected cells. Results: Soluble trimeric TRAIL protein was detected in CD20 positive lymphoma cells but not in CD20 negative lymphoma cells after infection with AdP20-stTRAIL ( P <0.05). Overexpression of stTRAIL in BJAB cells resulted in a significant increase in apoptotic cell death ( P <0.05). Conclusion: The CD20 promotor is capable of enhancing stTRAIL transcription in CD20 positive lymphoma cells, thereby having significant clinical implications in targeted cancer therapy.
Keywords:
Project Supported:
Projects supported by the National Natural Science Foundation for Young Scientists of China（No.81400176）
Clc Number:
